title: Osteonecrosis of maxilla secondary to bisphosphonate therapy: a case report.
abstract: Bisphosphonate chemotherapy is commonly used in the treatment of bone diseases such as osteoporosis, Paget disease, and multiple myeloma and to limit bone pain and hypercalcemia associated with malignant metastatic bone lesions. The introduction of bisphosphonate therapy has improved the quality of life in a vast majority of patients. However, since 2003 a growing number of reports have described necrotic bone lesions (bisphosphonate-associated Osteonecrosis of the jaw [BR-ONJ]) a bone lesion affecting maxillofacial bones in patients who have received high dosage chemotherapy with intravenous bisphosphonate therapy especially when the patient undergoes subsequent dental procedures. Sequential removal of sequestra as required seems to be the current conservative approach, but if large-volume debridement becomes necessary, removal of the bone sequestrum with minimal epithelial manipulation associated with topical and systemic antibiotics seem to be the treatment modality of choice. In our case, surgical salvage was performed successfully for BR-ONJ. Our experience indicates that with appropriate technique, primary surgical treatment may offer benefit to selected patients with BR-ONJ.
authors.affiliation: Bhagwan Mahaveer Jain Hospital, Bangalore, Karnataka.
authors.forename: Trupti
authors.initials: T
authors.lastname: Kolur
authors.affiliation: Bhagwan Mahaveer Jain Hospital, Bangalore, Karnataka.
authors.forename: Sanjiv C
authors.initials: SC
authors.lastname: Nair
authors.affiliation: Bhagwan Mahaveer Jain Hospital, Bangalore, Karnataka.
authors.forename: Balasubramanya
authors.initials: B
authors.lastname: Kumar
keywords: Bisphosphonate; Maxilla; Osteonecrosis
references.citation: Clin Cancer Res. 2002 May;8(5):1080-4
references.pmid: 12006522
references.citation: Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Oct;102(4):433-41
references.pmid: 16997108
references.citation: J Clin Oncol. 2006 Mar 20;24(9):1475-7
references.pmid: 16549843
references.citation: Med J Aust. 2005 Apr 18;182(8):413-5
references.pmid: 15850439
references.citation: J Clin Oncol. 2003 Nov 15;21(22):4253-4
references.pmid: 14615459
references.citation: Ann Intern Med. 2006 May 16;144(10):753-61
references.pmid: 16702591
references.citation: J Periodontol. 2006 Apr;77(4):738-43
references.pmid: 16584359
references.citation: Adv Drug Deliv Rev. 2005 May 25;57(7):959-71
references.pmid: 15876398
references.citation: J Oral Maxillofac Surg. 2007 Jul;65(7):1321-7
references.pmid: 17577496
references.citation: J Oral Maxillofac Surg. 2005 May;63(5):682-9
references.pmid: 15883944
references.citation: J Oral Maxillofac Surg. 2004 May;62(5):527-34
references.pmid: 15122554
references.citation: Bone. 2006 May;38(5):617-27
references.pmid: 16046206
references.citation: Dent Today. 2006 Aug;25(8):52, 54-7
references.pmid: 16925161
references.citation: N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102
references.pmid: 16003837
references.citation: J Oral Maxillofac Surg. 2005 Nov;63(11):1567-75
references.pmid: 16243172
references.citation: J Oral Maxillofac Surg. 2003 Sep;61(9):1104-7
references.pmid: 12966490
references.citation: J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7
references.pmid: 12966493